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Invasive fungal infections in patients with acute myeloid
leukemia and in those submitted to allogeneic hemopoietic
stem cell transplant: who is at highest risk?
To the Editor:
Invasive fungal infections (IFIs) are a growing cause
of morbidity and mortality in patients with acute
myeloid leukemia (AMLs) and in recipients of allogeneic
hemopoietic stem cell transplantation (allo-HSCTs) (1–6).
It is widely debated if either allo-HSCTs or AMLs are to
be considered at higher risk, but no data comparing the
two categories of patients have been reported in
literature so far.
This cohort study has been conducted from January
1999 to December 2003 in hematology wards located
throughout Italy. The study was aimed at evaluating the
incidence and mortality for IFIs in adult AMLs and in
patients submitted to all types of allo-HSCT procedures;
a comparison between the two categories of patients was
carried out.
EORTC ⁄MSG consensus criteria were used to deﬁne
IFIs (7). Only infections that were classiﬁed as ‘proven’
or ‘probable’ were included in the data analysis. Overall
and IFI-attributable mortality rates (IFI-AMR) were
estimated. IFI-AMR was deﬁned as a progression of sep-
sis-related symptoms or of the involved organ failure in
the absence of other morbid condition thought to cause
death. Outcome was assessed on the 150th day after IFI
diagnosis.
During the 5-yr study, 1596 new patients received
intensive chemotherapy for AML and 679 were submit-
ted to allo-HSCT procedures in the nine participating
centers. Proven or probable IFIs were documented in
270 AMLs (174 moulds and 96 yeasts) (incidence 16.9%)
and in 56 allo-HSCTs (43 moulds and 13 yeasts)
(incidence 8.2%). All yeast infections were sustained by
Candida spp. Conversely, mould infections were mostly
caused by Aspergillus spp (96% in AML and 91% in
HSCT); only a few cases due to rare agents were
observed.
Signiﬁcant differences emerged from the comparison
of IFI incidence rates in AMLs and allo-HSCTs. The
overall mortality rate for fungal infection was 5.9% in
AMLs and 5.7% in allo-HSCTs, with an IFI-AMR of
34.8% and 69.6% respectively (Table 1). Furthermore,
we separately analyzed mould and yeast infections. In
yeast infections, the incidence was higher in AMLs
(P-value <0.001), while differences in AMR were not
statistically signiﬁcant (P-value 0.105). As for moulds,
signiﬁcant differences in both incidence rate and AMR
were found in AMLs and allo-HSCTs (P-value <0.001).
Data about mortality rate became more impressive
after having compared AML patients treated with
chemotherapy (174 pts) to those treated with allo-HSCT
(21 pts). Mortality reached 90.5% in transplanted
patients (RR 2.58, CI95% 2.02–3.3, P-value <0.001).
IFIs appeared both during the early and late phase
after allo-HSCT. Interestingly in moulds infections only,
AMR resulted higher for those infections occurring
within 100 d from transplant (AMR 85% in early vs.
56% in late aspergillosis, P-value 0.04); it means that
patients receiving allo-HSCT continue to be at risk for
IFIs even after 100 d, but risk of mortality decreases
during the post-engraftment phase.
Table 1 Comparison between AML and allo-HSCT patients in nine centers
No. cases ⁄No. patients Incidence (CI95%) P-value No. exitus ⁄No. cases AMR (CI95%) P-value
IFIs
AML 270 ⁄ 1596 16.9% (15.4–19.1) <0.001 94 ⁄ 270 34.8% (29.2–40.6) <0.001
Allo-HSCT 56 ⁄ 679 8.2% (6.4–10.5) 39 ⁄ 56 69.6% (56.7–80.6)
Moulds
AML 174 ⁄ 1596 10.9% (9.4–12.5) <0.001 61 ⁄ 174 35% (28.8–43.0) <0.001
Allo-HSCT 43 ⁄ 679 6.3% (4.7–8.4) 32 ⁄ 43 74.4% (59.9–85.7)
Yeasts
AML 96 ⁄ 1596 6% (4.9–7.3) <0.001 33 ⁄ 96 34.4% (25.4–44.3) 0.105
Allo-HSCT 13 ⁄ 679 1.9% (1.1–3.2) 7 ⁄ 13 53.8% (27.4–78.7)
IFIs, invasive fungal infections; AML, acute myeloid leukaemia; allo-HSCT, allogenic haematopoietic stem cell transplantation; AMR, attributable
mortality rate.
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Our data conﬁrm that AML constitutes the category
most exposed to the risk of developing an IFI. This is
probably due to some host factors; in fact, it is well
known that AMLs are frequently colonized by fungi at
diagnosis because of the daily inhalation of conidia; in
such patients fungal agents may become virulent and a
systemic dissemination may occur when spores are not
cleared out because of the depressed immune defenses
(i.e. neutropenia due to bone marrow invasion and
chemotherapy). Conversely, patients undergoing HSCT
are generally more selected thanks to a good clinical per-
formance status. Furthermore, persistent, profound neu-
tropenia and the breakdown of physical barriers, which
represent important risk factors for IFIs, occur in almost
all AMLs undergoing intensive chemotherapy; on the
contrary, acute and chronic GVHD, the major risk
factor for IFIs in allo-HSCTs, develops only in a part
of patients depending on the particular transplant
procedure they are submitted to.
IFI-AMR was signiﬁcantly higher in allo-HSCTs, par-
ticularly in patients developing moulds infection within
100 d from transplant. Differences in outcome are proba-
bly related to the treatment intensity, the coexistence of
other complications (i.e. GVHD and steroid therapy,
CMV disease), the use of antifungal prophylaxis and the
immunosuppression complexity and duration. In fact,
the recovery of immune impairment after allo-HSCT
procedures occurs late and depends on the use of immu-
nosuppressive agents required for the treatment of
GVHD, while the recovery of chemotherapy induced
neutropenia usually occurs within a few weeks or days
and represents the major factor inﬂuencing the outcome
of IFIs in AMLs.
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